How do you reconcile the differing outcomes of the MATTERHORN and KEYNOTE-585 trials when determining systemic treatment approach for gastric/GEJ adenocarcinoma?

As it turns out, the outcomes are much more similar than dissimilar. While we all know MATTERHORN was a clearly positive study, KEYNOTE-585 was essentially also a positive study, obscured by a negative overall interpretation and undermined by its complicated statistical design.

Specifically, 804 pati...

It’s important to understand that the chemotherapy was not standardized in the same way in KEYNOTE-585 as it was in MATTERHORN. In KEYNOTE-585, only a small minority of patients received FLOT compared to ECF/5FU/cisplatin. FLOT4 previously showed the superiority of FLOT compared to a cisplatin regim...